



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07K 1/00, C07H 21/04, A61K 38/00, 48/00, A01N 63/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 95/31472</b> <b>(43) International Publication Date:</b> 23 November 1995 (23.11.95)
<b>(21) International Application Number:</b> PCT/US95/05946 <b>(22) International Filing Date:</b> 11 May 1995 (11.05.95) <b>(30) Priority Data:</b> 08/245,337 18 May 1994 (18.05.94) US <b>(71) Applicant:</b> BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West Seventh Street, Austin, TX 78701 (US). <b>(72) Inventors:</b> GHOBRIAL, Rafik, R.; 4822 Meadowglen Drive, Pearland, TX 77584 (US). STEPKOWSKI, Stanislaw, M.; 2670-D Holly Hall, Houston, TX 77054 (US). KAHAN, Barry, D.; 4 Rain Hollow, Houston, TX 77024 (US). <b>(74) Agent:</b> SIMPSON, Jan, K.; Pravel, Hewitt, Kimball & Krieger, P.C., 1177 W. Loop South, 10th floor, Houston, TX 77027-9095 (US).		<b>(81) Designated States:</b> AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> CHIMERIC MHC CLASS I ANTIGENS FOR INDUCING ALLOGRAFT TOLERANCE		
<b>(57) Abstract</b>  Chimeric MHC Classe I molecules having a recipient-type N-terminus, a donor-type alpha-1 helical region, and a recipient-type alpha-2 domain induce tolerance to donor grafts when administered to the recipient at time of transplantation.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

TITLE: CHIMERIC MHC CLASS I ANTIGENS FOR  
INDUCING ALLOGRAFT TOLERANCE

FIELD OF THE INVENTION

This invention relates to recombinant major histocompatibility complex (MHC) molecules, and specifically to chimeric MHC Class I molecules engineered to induce allograft tolerance. This invention also relates to methods for inducing tolerance to a transplanted allograft by administering to the transplant recipient a chimeric MHC Class I molecule having self-type regulatory domains and donor-type immunogenic domains.

BACKGROUND OF THE INVENTION

The major histocompatibility complex (MHC) includes histocompatibility antigens, polymorphic membrane glycoproteins found on the surface of nearly all cells. One individual simultaneously expresses polymorphic forms from a large pool of alleles in the population. Rejection of foreign tissue transplants is initiated by antibody and cytotoxic lymphocyte (CTL) recognition of Class I histocompatibility antigens. T-cell receptors only recognize foreign antigens that are associated with a particular histocompatibility antigen molecule.

As known to one of skill in the art, MHC molecules bind an intracellular foreign peptide antigen, transport the bound antigen to the surface of the cell membrane, and present the antigen for recognition by T-cells. T-cell recognition of antigen-bound MHC molecules then initiates a cascade of events in the immune response.

In organ transplantation, despite major advances in surgical techniques and the development of new drugs, the majority of transplant recipients remain at high risk for rejection. Currently available therapies to prevent rejection rely on broad spectrum immunosuppressive drugs such as cyclosporin A (CsA), which must be taken through out the individual's life. The cumulative effects of such long-term immunosuppression include opportunistic infections, cancers, and drug-specific toxicity. It would be of great utility to develop a therapeutic system administered only in the perioperative period which could thereby avoid the long-term effects of immunosuppression.

Prior attempts to alleviate organ transplant rejection using the MHC molecule have included administration of whole donor cells, which express donor-type MHC antigens. This method requires pre-operative administration of the alloantigen, and thus has only limited clinical applicability because of the need for donor-identification well in advance of the time of transplantation. It would be highly desirable to develop an effective therapeutic system which could be administered at the time of transplantation.

#### SUMMARY OF THE INVENTION

It has now been found that the MHC Class I molecule includes specific functional domains important in the generation of an immune response. A dominant allogenic epitope was mapped to the helical portion of the alpha-1 domain and a sub-dominant allogeneic epitope was mapped to the N-terminus of the alpha-1 domain of MHC Class I molecules. Unexpectedly, the alpha-2 domain was shown to lack immunogenic sequences, but to have an important regulatory role in recognition

of a foreign antigen. The substitution of donor-type immunodominant alpha-1 helical epitope for the wild-type (recipient) immunodominant epitope converted the immunogenic MHC Class I molecule to a tolerogen when  
5 the flanked by recipient-type alpha-1N-terminus and alpha-2 domain sequences. Treatment of transplant recipients with extracts of transfected cells bearing these "quasi-self" chimeric MHC Class I molecules together with a 7-day cyclosporine (CsA) course induced  
10 donor-specific transplantation tolerance. This chimeric molecule provides a clinically relevant system for the induction of allograft tolerance.

#### BRIEF DESCRIPTION OF THE FIGURES

15 Figure 1 is a diagrammatic representation of an expression vector for expression of WT-RT1.A<sup>a</sup> in BUF hepatoma cells. The gene encoding WT-RT1.A<sup>a</sup> was subcloned in the proper orientation at the EcoR I site of the pSG5 mammalian expression vector containing the  
20 SV40 promotor and enhancer.

Figure 2 is a graphic representation of WT-RT1.A<sup>a</sup> detection on the cell surfaces of control and transfected 7316A BUF hepatoma cells by exposure to a fluoresceinated rabbit anti-rat IgG antibody (1:250  
25 dilution; non-shaded region) or with pre-coated anti-RT1<sup>a</sup> antibody (shaded region). The percent of stained cells is shown in each figure.

Figure 2A shows non-transfected hepatoma cells that were exposed to polyclonal anti-RT1<sup>a</sup> antibody.

30 Figure 2B shows non-transfected hepatoma cells that were exposed to R2/15S anti-rat RT1.A<sup>a</sup> Class I polymorphic monoclonal antibody.

Figure 2C shows non-transfected hepatoma cells that were exposed to MRC OX18 anti-rat RT1A class I  
35 monomorphic monoclonal antibody.

Figure 2D shows hepatoma cells transfected with WT-RT1.A<sup>a</sup> that were exposed to polyclonal anti-RT1<sup>a</sup> antibody.

5 Figure 2E shows hepatoma cells transfected with WT-RT1.A<sup>a</sup> that were exposed to R2/15S anti-rat RT1.A<sup>a</sup> Class I polymorphic monoclonal antibody.

Figure 2F shows hepatoma cells transfected with WT-RT1.A<sup>a</sup> that were exposed to MRC OX18 anti-rat RT1A class I monomorphic monoclonal antibody.

10 Figure 3 is a graphic representation of dose-dependent immunization toward ACI (RT1<sup>a</sup>) by WT-RT1.A<sup>a</sup> transfectants. WF (RT1<sup>u</sup>) rats were injected with 10<sup>5</sup> to 2 X 10<sup>7</sup> cells 7 days prior to ACU heart grafts. The dashed horizontal line represents the mean survival  
15 time of ACI grafts in untreated WF recipients. Subcutaneous injection (filled circles); intravenous injection (filled squares); and portal vein injection (filled diamonds) are shown. Normal hepatoma cells given by subcutaneous administration (open circles);  
20 intravenous injection (open squares) or by the portal vein (open diamonds) are also shown.

Figure 4 is a schematic illustration of class I RT1.A<sup>a</sup> showing the chimeric substitution sites. N<sup>HLA-A2.1</sup>-RT1.A<sup>a</sup> contains four residue changes (at 5, 9,  
25 11, and 17) at the N-terminus which alters the sequence of the first 20 amino acids (first beta-strand and loop) to that of HLA-A2.1. The chimera  $\alpha$ -1h<sup>u</sup>-RT1.A<sup>a</sup> contains ten amino acid changes in the  $\alpha$ -helix (51-90) of the  $\alpha$ -1 domain (at positions 58, 62, 63, 65, 66, 69,  
30 70, 73, 77, and 80) to alter this region to that of RT1.A<sup>u</sup>. The chimera  $\alpha$ -2d<sup>u</sup>-RT1.A<sup>a</sup> has eight amino acid changes along the first beta-strand and the  $\alpha$ -helix (at positions 97, 105, 148, 151, 152, 169, 174, and 182) of the  $\alpha$ -2 domain (91-182) which changes this domain to

that of RT1.A<sup>u</sup>. TM is the trans-membrane domain and CYT is the cytoplasmic domain.

Figures 5A-C are a series of photographs showing the production of altered RT1.A<sup>a</sup> cDNA by PCR Gene SOEing. The positions of changed amino acids are indicated above each lane.

Figure 5A shows production of N<sup>HLA-A2.1</sup>-RT1.A<sup>a</sup>: The overlapping products of PCR #1, 140 base pairs (lane 2) and PCR #2, 1490 base pairs (lane 3) were SOEd in PCR #3 (lane 4).

Figure 5B shows production of  $\alpha$ -1h<sup>u</sup>-RT1.A<sup>a</sup>: The overlapping products of PCR #1, 300 base pairs (lane 2) and PCR #2, 1310 base pairs (lane 3) were SOEd in PCR #3 (lane 4).

Figure 5C shows production of  $\alpha$ -2d<sup>u</sup>-RT1.A<sup>a</sup>: Four overlapping PCR products 400, 150, 120 and 990 b.p. (lanes 2-5) were SOEd together in PCR #5 (lane 6).

Figure 6 shows the nucleotide sequences of the chimeras N<sup>HLA-A2.1</sup>-RT1.A<sup>a</sup>,  $\alpha$ -1h-RT1.A<sup>a</sup> and  $\alpha$ -2d<sup>u</sup>-RT1.A<sup>a</sup>. Full lengths cDNAs were sequenced in both directions. The shown sequences represent only the changed amino acid residues and the corresponding nucleotide changes (underlined). The dots indicate no alteration from the WT-RT1.A<sup>a</sup> sequences.

Figure 7 is a graph showing detection of chimeric RT1.A<sup>a</sup> on the cell surfaces of transfected BUF hepatoma cells. The RT1.A<sup>a</sup> cDNAs were exposed to fluoresceinated rabbit anti-rat IgG antibody (1:250 dilution) without (non-shaded) or with (shaded) pre-coating with polyclonal anti-RT1.A<sup>a</sup> (1:8 dilution) antibody.

Figure 7A shows detection of RT1.A<sup>a</sup> on non-transfected hepatoma cells.

Figure 7B shows detection of RT1.A<sup>a</sup> on cells transfected with WT-RT1.A<sup>a</sup>.

Figure 7C shows detection of RT1.A<sup>a</sup> on cells transfected with  $\alpha$ -1h<sup>u</sup>-RT1.A<sup>a</sup>.

Figure 7D shows detection of RT1.A<sup>a</sup> on cells transfected with  $\alpha$ -1d<sup>u</sup>-RT1.A<sup>a</sup>.

5        Figure 7E shows detection of RT1.A<sup>a</sup> on cells transfected with N<sup>HLA-A2.1</sup>-RT1.A<sup>a</sup>.

Figure 8 is a graph showing immunogenicity of chimeric RT1.A<sup>a</sup> antigens in WF hosts, represented as dose-dependent immunization toward ACI (RT1<sup>a</sup>). WF rats  
10        were injected subcutaneously with  $10^5$ - $2 \times 10^7$  cells 7 days prior to an ACI heart allograft challenge. Mean survival time was calculated in days. There were at least five rats in each group. The dashed horizontal line represents the mean survival time ( $5.4 \pm 0.5$  days)  
15        of ACI grafts in untreated WF recipients. The solid horizontal line (50% index) represents 50% reduction of survival time. Subcutaneous injection of ACI spleen cells (filled triangles) displayed 2.6 times and 7.6 times greater immunogenicity than WT-RT1.A<sup>a</sup> (filled  
20        circles) and N<sup>HLA-A2.1</sup>-RT1.A<sup>a</sup> (filled squares) transfectants, respectively. The chimeras  $\alpha$ -1h<sup>u</sup>-RT1.A<sup>a</sup> (open squares),  $\alpha$ -2d<sup>u</sup>-RT1.A<sup>a</sup> (open diamonds) and non-transfected hepatoma cells (filled diamonds) displayed  
25        no immunogenic ability.

25        Figure 9 is a graph showing the frequency of anti-ACI (RT1<sup>a</sup>) cytotoxic T cells in lymph node cells obtained from WF rats 7 days following administration of  $2 \times 10^7$  ACI spleen cells (filled triangles), WT-RT1.A<sup>a</sup> (filled circles), N<sup>HLA-A2.1</sup>-RT1.A<sup>a</sup> (filled squares),  
30         $\alpha$ -1h<sup>u</sup>-RT1.A<sup>a</sup> (open squares),  $\alpha$ -2d<sup>u</sup>-RT1.A<sup>a</sup> (open diamonds) transfectants, non-transfected hepatoma cells (filled diamonds), and naive, non-treated hosts (open circles). Data was generated by limiting dilution analysis.



Figures 10 A-C are graphs showing anti-RT1<sup>a</sup> alloantibody production in WF rats treated with ACI spleen cells or chimeric RT1.A<sup>a</sup> transfectants: ACI spleen cells (filled triangles), WT-RT1.A<sup>a</sup> (filled circles), N<sup>HLA-A2.1</sup>-RT1.A<sup>a</sup> (filled squares),  $\alpha$ -1h<sup>u</sup>-RT1.A<sup>a</sup> (open squares), and  $\alpha$ -2d<sup>u</sup>-RT1.A<sup>a</sup> (open diamonds) transfectants. Control sera was obtained from naive, non-treated hosts (open circles) or from WF rejectors of ACI hearts (filled diamonds).

Figure 10 A shows the presence of IgG-binding alloantibodies. Data are presented as mean channel shift.

Figure 10 B shows the presence of IgM-binding alloantibodies. Data are presented as mean channel shift.

Figure 10 C shows the presence of anti-ACI cytotoxic alloantibodies. Data are presented as % specific lysis.

Figure 11 is a graph showing the effect of subcutaneous administration of chimeric RT1.1A<sup>a</sup> antigens in ACI hosts on in vivo immunization of ACI (RT1<sup>a</sup>) recipients of WF (RT1<sup>u</sup>) heart allografts. ACI rats were untreated (broken lines) or immunized with WT-RT1.A<sup>a</sup> (filled circles), N<sup>HLA-A2.1</sup>-RT1.A<sup>a</sup> (filled squares),  $\alpha$ -1h<sup>u</sup>-RT1.A<sup>a</sup> (open squares),  $\alpha$ -2d<sup>u</sup>-RT1.A<sup>a</sup> (open diamonds) transfectants or WF spleen cells (filled diamonds) seven days prior to WF (RT1<sup>u</sup>) heart allograft challenge.

Figure 12 is a graph showing the frequency of anti-WF (RT1<sup>u</sup>) cytotoxic T cells in lymph nodes obtained from ACI rats following treatment with WT-RT1.A<sup>a</sup> (filled circles), N<sup>HLA-A2.1</sup>-RT1.A<sup>a</sup> (filled squares),  $\alpha$ -1h<sup>u</sup>-RT1.A<sup>a</sup> (open squares),  $\alpha$ -2d<sup>u</sup>-RT1.A<sup>a</sup> (open diamonds) transfectants, WF spleen cells (filled

diamonds), or non-treated naive hosts (open circles). Data were obtained by limiting dilution analysis.

Figure 13 is a graph showing tolerance induction by peri-transplant administration of e-HAg-chimeras combined with cyclosporine. ACI (RT1<sup>a</sup>) recipients of WF (RT1<sup>u</sup>) hearts were untreated (broken lines) or treated with a 7 day course of oral CsA alone (solid lines) or in combination with a single injection of e-HAg obtained from WT-RT1.A<sup>a</sup> (filled circles), N<sup>HLA-A2.1</sup>-RT1.A<sup>a</sup> (filled squares),  $\alpha$ -1h<sup>u</sup>-RT1.A<sup>a</sup> (open squares),  $\alpha$ -2d<sup>u</sup>-RT1.A<sup>a</sup> (open diamonds) transfectants, WF liver cells (filled arrowheads), or non-transfected BUF hepatoma cells (filled diamonds)

#### 15        DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT          MHC Class I Molecules

Class I transplantation antigens of the major histocompatibility complex (MHC) are cell surface glycoproteins which present antigens to cytotoxic T-cells. They are heterodimeric and composed of a polymorphic, MHC-encoded, approximately 45KD heavy chain, which is non-covalently associated with an approximately 12KD beta-2 microglobulin (beta-2m) light chain. The H-2 system of the mouse and the HLA system of the human, as well as the RT1 system of the rat have been studied. Among the several allelic types of Class I molecules only certain ones affect graft survival in each species (HLA-A, B in humans; H-2K, D in mice; and RT.1A in rat).

30        The extracellular portion of the MHC Class I heavy chain is divided into three domains, alpha-1, alpha-2, and alpha-3, each approximately 90 amino acids long and encoded on separate exons. The alpha-3 domain and beta-2 m are relatively conserved and show amino-acid  
35        sequence homology to immunoglobulin constant domains.

The polymorphic alpha-1 and alpha-2 domains show no significant sequence homology to immunoglobulin constant or variable regions, but do have weak sequence homology to each other. The membrane-distal polymorphic alpha-1 (approximately 90 amino acids) and alpha-2 (approximately 92 amino acids) domains each include four anti-parallel, beta-pleated sheets bordered by one alpha-helical regions, (the first from the alpha-1 and the second from the alpha-2 domain). The alpha-2 domain is attached to the less-polymorphic, membrane-proximal alpha-3 (approximately 92 amino acids) domain which is followed by a conserved trans-membrane (25 amino acids) and an intra-cytoplasmic (approximately 30 amino acids) segment. The rat, mouse, and human Class I MHC molecules are believed to have similar structural characteristics based upon known nucleotide sequences of the various MHC Class I molecules.

For a review of the structure and function of the MHC Class I molecules, see, for example: Matsumura et al., 1992, Science 257:927-934; Bjorkman and Parham, 1990, Annu. Rev. Biochem., 59:253-288; and Germain, 1994, Cell, 76:287-299.

#### Immunodominant Epitope

The alpha-1 domain has now been shown to contain an immunodominant, immunogenic epitope in the alpha-1 helical region and a subdominant, N-terminal allogenic determinant. The alpha-2 domain does not contain an immunogenic epitope.

That the immunodominant immunogenic epitope was contained in the alpha-1 helical region was shown by the following experiments. A chimeric mutant of the RT1.A<sup>a</sup> molecule was constructed by replacing the alpha-1 helical region with a corresponding alpha-1

helical region of an RT1.A<sup>u</sup> gene sequence. The protein produced from this chimeric gene was unable to sensitize RT1<sup>b</sup> (BUF) host toward transplanted RT1.A<sup>a</sup> bearing ACI grafts. In contrast, the same chimeric peptide did sensitize RT1<sup>b</sup> (BUF) host toward WFu allografts which express the RT1.A<sup>u</sup> antigen. Additional chimeras which contained the alpha-1<sup>a</sup> helical epitope did immunize both BUF and WFu hosts against the ACI grafts.

#### Subdominant Immunogenic Epitope

The presence of a subdominant immunogenic epitope in the N-terminal segment of the alpha-1 domain was demonstrated by the following experiments: The wild type RT1.A<sup>a</sup> gene was altered by replacing the N-terminal epitope (approximately 20 amino acids) with the corresponding N-terminal epitope of the human HLA-A2.1 sequence. This substitution resulted in reduced immunogenicity toward RT1<sup>a</sup> (ACI) grafts in WFu hosts, indicating the presence of an immunogenic epitope in the N-terminus. However, the N-terminal<sup>a</sup> epitope alone, present in the RT1.A<sup>a</sup> chimera having the alpha-1<sup>a</sup> helical sequence replaced with the corresponding alpha-1<sup>u</sup> helical sequence failed to sensitize either BUF (RT1<sup>b</sup>) or WFu (RT1<sup>u</sup>) rats against ACI (RT1<sup>a</sup>) grafts. The subdominant epitope corresponds to the first beta-strand and loop of the alpha-1 domain.

#### Regulatory Epitope

In contrast to the alpha-1 domain, the alpha-2 allogenic domain lacked potent immunogenic determinants. This was shown by two experiments: The wild type RT1.A<sup>a</sup> gene was altered by replacing the entire alpha-2<sup>a</sup> domain with the corresponding alpha-2<sup>u</sup> domain sequences. Neither the protein encoded by this

chimeric gene nor the protein encoded by the chimeric gene containing alpha-1<sup>u</sup> helical sequences were able to immunize BUF (RT1<sup>b</sup>) recipients toward WFu (RT1<sup>u</sup>) or ACI (RT1<sup>a</sup>) heart allografts, respectively.

5       The flanking of immunogenic epitopes by syngenic sequences directs host immune responses toward unresponsiveness. This observation is based on the result of two experiments. First, WFu (RT1<sup>u</sup>) hosts injected with transfected cells bearing an N-terminal<sup>a</sup> and alpha-1 helical<sup>a</sup> immunogenic epitopes together with  
10       an alpha-2<sup>u</sup> domain sequences were not sensitized toward RT1<sup>a</sup> (ACI) allografts. Further, these recipients failed to produce anti-ACI alloantibodies and displayed the presence of negative regulatory T-cells that  
15       inhibited the function of allospecific CTLs. The same chimeric molecules did sensitize BUF (RT1<sup>b</sup>) recipients to accelerate the rejection of ACI (RT1<sup>a</sup>) hearts. Secondly, ACI recipients treated with transfectants bearing the dominant donor-type alpha-1<sup>u</sup> helical  
20       immunogenic epitope flanked by recipient-type N-terminal<sup>a</sup> and alpha-2<sup>a</sup> sequences prolonged (WFu) RT1<sup>u</sup> heart allograft survival. This coincided with reduced fTc directed against WFu alloantigens. The same chimeric molecule induced accelerated rejection of WFu  
25       (RT1<sup>u</sup>) hearts in BUF (RT1<sup>b</sup>) recipients. This effect indicates that donor-type immunogenic epitopes displayed on recipient-type Class I molecules become tolerogenic.

### 30       Chimera Induced Tolerance

      The role of the specific Class I MHC alloantigens in induction of unresponsiveness toward allografts is clear from experiments in mice. Extracts of transfected cells bearing the alpha-1<sup>u</sup>-helix flanked by  
35       recipient N-terminal<sup>a</sup> and alpha-2<sup>a</sup> sequences were

injected once via the portal vein at the time of transplantation (day 0) in conjunction with a seven-day course of CsA therapy. This treatment induced donor-specific tolerance to WFu (RT1<sup>u</sup>) heart allografts in  
5 80% of ACI (RT1<sup>a</sup>) recipients. In contrast, extracts from wild type RT1.A<sup>a</sup>, WFu Class I RT1u<sup>a</sup> bearing hepatocytes, and chimeric molecules having N-terminus antigen substitution or alpha-2 domain substitution were ineffective in preventing graft rejection. Thus,  
10 modification of Class I MHC alloantigens was used to develop chimeric Class I molecules that induced a negative immune response to intact wild type antigens. Tolerance induction using chimeric (quasi-self) Class I molecules represents a novel, clinically applicable  
15 approach to preventing graft rejection.

#### Useful Chimeras

Useful chimeric molecules of the present invention are MHC Class I antigens having a recipient-type N-terminal region of the alpha-1 domain, recipient-type  
20 alpha-2 domain, and a donor-type alpha-1 helical region. It is understood by one of skill in the art that the chimeric MHC Class I molecules or genes encoding them may be modified or altered without  
25 significantly changing the immunogenic and regulatory epitopes and thus without altering the function of the chimeras of the present invention. Useful chimeras of the present invention, in three dimensional form, preferably present a surface sufficient for binding and  
30 presenting a foreign peptide. The chimeric MHC Class I molecules of the present invention include a donor-type immunogenic determinant (alpha-1h), an recipient type N-terminal immunogenic determinant (alpha-1N), and a recipient-type alpha-2 determinant.

Useful chimeric molecules of the present invention may be prepared and screened in the following manner. Chimeric genes may be prepared by recombinant methods known to those of skill in the art. A preferred method is the PCR-based method of gene splicing with overlap extension described in Example 2. A gene encoding a specified MHC Class I antigen is altered to replace the immunodominant  $\alpha$ -1h epitope with the corresponding immunodominant  $\alpha$ -1h epitope of a different MHC Class I molecule. Preferably, the conserved epitope is of a recipient's MHC Class I type and the sequences replacing the immunodominant epitope are derived from a specified donor's MHC Class I type. Cells transfected with the genes encoding the chimeric proteins express these proteins, which are extracted, e.g., with three molar KCl. Approximately 10 milligrams of the extract containing the chimeric proteins is injected into the portal vein of a model recipient (e.g. rat) at the time of donor organ transplantation (day 0). Transplanted animals are also given a seven day oral CsA course (10 mg/kg, days 0-6). Mean animal survival rate is calculated for test and control animals. Useful chimeric molecules of the present invention are those which can induce donor-specific transplantation tolerance.

Specific chimeric MHC Class I genes encoding MHC Class I proteins that produce a tolerogenic effect include gene sequences encoding the recipient's-type N-terminal portion of the  $\alpha$ -1 domain (approximately 20 amino acids) and the  $\alpha$ -2 domain and sequences encoding the donor's-type helical region of the  $\alpha$ -1 domain. Preferably, the substituted donor sequences include the polymorphic region of the  $\alpha$ -1 helical region.

The chimeric MHC Class I molecules of the present invention may be administered to transplant recipients

preferably at the time of transplantation, by methods known in the art. Preferably, the molecules are injected, most preferably intravenously. The chimeric molecules may be administered as purified glycoprotein, as extracts or as whole cells expressing the molecules. The appropriate dose and administration regimen may be determined by the administering physician by known methods.

In a preferred embodiment, extracts of cells transfected with genes encoding the chimeric molecules are administered peri-operatively together with a seven day course of CsA therapy.

#### EXAMPLES

##### EXAMPLE 1

##### CHARACTERIZATION OF THE EFFECT OF WILD TYPE-RT1.A<sup>a</sup>

Wild type RT1.A<sup>a</sup> cDNA was obtained from J. Howard (Rada et al., 1990, PNAS USA, 87:2167-2171) was subcloned in the proper orientation at the ECORI site of the mammalian expression vector pSG5 containing the SV40 promoter and enhancer (Stratagene, LaJolla, CA). This vector was co-transfected into BUF (RT1<sup>b</sup>) Morris hepatoma 7316 A cells (Masuji et al., Acta Med. Okayama, 28:281-293, 1974) with pSV2-NEO containing the neomycin resistance gene, using the lipofectin reagent (GIBCO, Grand Island, NY; Felinger et al., 1987). Lipofectin (25 $\mu$ l) plasmid DNA (10 $\mu$  pSG5-RT1.A<sup>a</sup>:pSU2NEO, 10:1) complexes were added to 2 x 10<sup>5</sup> cells in 4 ml serum-free medium (complete RPMI, Sigma, St. Louis, MO) in 60 ml culture dishes. Following a six hour incubation at 37°C, the medium was replaced with ten percent Fetal Calf Serum-RPMI. After 48 hours of further incubation, stable transfectants were selected by the addition of 400 $\mu$ g/ml (final concentration) Geneticin (G418, GIBCO, Grand Island, NY) to the culture medium surviving



colonies were expanded and analyzed for surface expression of RT1.A<sup>a</sup>.

The transfected cells were analyzed by FACS to detect RT1.A<sup>a</sup> on the cell surfaces by exposing the cells to a fluorescinated rabbit anti-rat IgG antibody (1:250 dilution) or by precoating with specific antibodies.

#### Flow cytometry analysis

To detect surface expression of wild-type RT1.A<sup>a</sup> on transfected BUF (RT1<sup>b</sup>) hepatoma cells, transfected and non-transfected BUF hepatoma cells were suspended in Hank's Balanced Salt Solution (HBSS; Sigma, St. Louis, MO) supplemented with 5% fetal calf serum (FCS). Approximately  $3 \times 10^3$  cells were incubated at 4°C. for 30 minutes in 50  $\mu$ l of 1:4, 1:8 and 1:16 dilution of polyclonal BUF (RT1<sup>b</sup>) antibodies raised against WT-RT1.A<sup>a</sup> or 50  $\mu$ l of 1:150 dilution of R2/15S anti-rat RT1.A<sup>a</sup> class I polymorphic monoclonal antibody (Bioproducts for Science, Indianapolis, IN) or anti-rat RT1.A class monomorphic monoclonal antibody MRC OX 18 (Bioproducts for Science, Indianapolis, IN) After washing, 50  $\mu$ l of 1:250 dilution of fluorescein (FITC)-conjugated rabbit anti-rat Ig (Zymed labs, San Francisco, CA) was added to the cells. Following a second incubation, cells were washed and fixed with 1.5% paraformaldehyde. Cells stained only with FITC rabbit anti-rat Ig were used for measurement of background non-specific fluorescence. Analysis was performed on a Becton-Dickinson Laser Flow Cytometry System (Mountain View, CA). Data are presented as percent of cells with positive staining calculated as the difference between the sample's fluorescence and background staining.

As shown in Figure 2, FACS analysis of wild type RT1.A<sup>a</sup> stable transfectants demonstrated enhanced

(greater than 90%) positive staining with anti-RT1<sup>a</sup> polyclonal antibody or specific anti-RT1.A<sup>a</sup> Class I RT2/15S monoclonal antibody. In addition, staining with the anti-rat RT1A class monomorphic monoclonal antibody MRC OX18 demonstrated greater total surface expression of Class I molecules on transfected cells than on non-transfected cells.

Adult male inbred WFu (RT1<sup>a</sup>) rats (Harlan Sprague Dawley, Indianapolis, IN) were injected with  $1 \times 10^5$  -  $2 \times 10^7$  control or transfected cells 7 days prior to AC1 heart grafts. The mean survival time of the grafts was calculated.

#### Cardiac transplantation

Heterotopic cardiac transplants were harvested from donor rats (Harlan Sprague Dawley, Indianapolis, IN) and placed intra-abdominally as previously described (Ono and Lindsey, 1969, J. Thoracic Cardiovasc. Surg. 51: 225-229). Donor hearts were perfused through the aorta with chilled heparinized cardioplegic solution prior to retrieval by ligation of the vena cava and pulmonary veins after the recipients were anaesthetized with ketamine hydrochloride (Parke-Davis, Morris Plains, NJ; 0.1 mg/100 g weight). Infrarenal vena cava and aortic microvascular anastomosis to donor pulmonary artery and aorta were performed using 8-0 nylon sutures (Ethicon, Somerville, NJ). Cold ischemia time was less than 45 minutes. Cardiac activity was assessed by abdominal palpation. Data are presented as mean survival time (MST)  $\pm$  S.D. and compared using the t-test; a value of  $P < 0.05$  indicated statistical significance.

Subcutaneous injection of WFu rats approximately four to six weeks old, weighing about 160-200 g (RT1<sup>a</sup>) (Helen Sprague-Dowdy, Indianapolis, IN) with  $1-2 \times 10^7$  wild type RT1.A<sup>a</sup>-transfected BUF hepatoma cells, but

not control, non-transfected BUF (RT1<sup>b</sup>) hepatoma cells, seven days prior to ACI (RT1<sup>a</sup>) heart allograft challenge shortened the mean survival time of transplanted animals from  $5.4 \pm 0.5$  days to  $3 \pm 0.0$  days or  $2.8 \pm 0.4$  days, respectively ( $p < 0.001$ ). Intravenous delivery was less immunogenic, and the portal vein route was ineffective. These data are shown in Figure 3.

10

EXAMPLE 2THE PRODUCTION AND CHARACTERIZATION  
OF CHIMERIC RT1.A<sup>a</sup> CLASS I ANTIGENS

The polymerase chain reaction (PCR)-based method of gene splicing with overlap extension (gene SOEing) was used to produce three chimeric molecules using a panel of primers. This method is described in Horton et al., Biotechniques, 8:528 (1990), "Gene Splicing by Overlap Extension: Tailor-Made Genes Using the Polymerase Chain Reaction," which is hereby incorporated by reference for all purposes.

The plasmid pBS3.3/1 (Rada et al., 1990, PNAS USA, 87:2167-2171) containing wild-type RT1.A<sup>a</sup> cDNA, served as a template for PCR amplification reactions between 5' and 3' flanking "outside primers" A and L (see Table 1 for sequence data) that contain the Eco R I restriction site and two internal overlapping "SOEing" primers, which contained the base substitutions. The first PCR reaction used one  $\mu$ l of the 5' outside primer (500 ng), one  $\mu$ l of the first internal primer (500 ng), one  $\mu$ l dNTP (25 mM), one  $\mu$ l DNA template (one  $\mu$ g), ten  $\mu$ l of 10X hot tub DNA polymerase buffer, one  $\mu$ l of hot tub DNA polymerase (Amersham, Arlington, IL), and 85  $\mu$ l dH<sub>2</sub>O. A second PCR reaction used the second internal primer and the 3' flanking outside primer.

The PCR reactions were covered with mineral oil and subjected to two cycles of:

one minute denaturation at 94°C;  
two minutes annealing at 53°C; and  
5 three minutes elongation at 72°C,

followed by 23 cycles of:

one minute denaturation at 94°C;  
two minute annealing at 59°C; and  
three minute elongation at 72°C,

10 and ending with ten minute elongation at 72°C.

The two PCR products were electrophoresed in low melting agarose gels to yield the approximately sized DNA bands for excision and melting at 60°C. A third SOEing PCR reaction used the two outside flanking  
15 primers with five microliters from the melted gel slices of the first and second PCR reactions as DNA templates to yield a 1.6 kb RT1.A<sup>a</sup> DNA fragment, which was excised, eluted, ethanol precipitated, washed with 70% ethanol and dissolved in dH2O.

20 Primers used in these reactions are shown in Table 1:

TABLE 1

CODE	SEQ. I.D.	NUCLEOTIDE SEQUENCE (5'→3')
A	1	CAGGAATTCCGGGATCTCAGATG
B	2	GCCGGGCCGGGACACGGAGGTGAAGAAATACCGCATCGAGTGT G
C	3	CGTGTCCCGGCCCGGCCGCGGGGAGCCC
D	4	CTGCTCGTTTCCCTTGGCTTTCTGTGTCTCCCTCTCCCAATAG TCCGGCCCC
E	5	GCCAAGGGAACGAGCAGAATTACCGAGTGAGCCTGAGGAATC TGC GCGGC
F	6	CCACGTCACAGCCATACATCCTCTGGATGGTG
G	7	GTATGGCTGTGACGTGGGGACGGAGGGGAGC
H	8	AGCCCGATCCCACTTGTTC
I	9	GGAACAAGTGGGATCGGGCTGGTGTTCAGAGAGACTC
J	10	GGGGGATCTAAGCGCAGCAGTGTCTCCTTCCCGTGCTCCAGGT ATCTGCGGAGCCACTC
K	11	CTGCTGCGCTTAGATCCCCC
L	12	CGATAAGCTTGATATCCGAATCCGG

Internal primers B, C, D, and E were used to produce the N-terminus substitutions.

Six internal primers: F, G, H, I, J and K, were utilized in four initial separate PCR reactions followed by one SOEing reaction with primers A and L to alter the alpha-2 domain.

In these reactions, substitutions were made in the N-terminus (N), alpha-1 helical region ( $\alpha$ -1h) or alpha-2 domain ( $\alpha$ -2d) of wild type-RT1.A<sup>a</sup> cDNA. These gene sequences are schematically diagrammed in Fig. 4, and the constituents of the chimeras produced are shown in Table 2:

TABLE 2

MHC CLASS I GENE	N- TERMINUS SUBDOMIN ANT EPITOPE	$\alpha$ -1 HELICAL DOMINANT EPITOPE	$\alpha$ -2 DOMAIN REGULATOR Y EPITOPE
WT-RT1.A <sup>a</sup>	Rat-a	Rat-a	Rat-a
N <sup>HLA-A2.1</sup> - RT1.A <sup>a</sup>	HLA	Rat-a	Rat-a
$\alpha$ -2 <sup>u</sup> -RT1.A <sup>a</sup>	Rat-a	Rat-a	Rat-u
$\alpha$ -1h <sup>u</sup> -RT1.A <sup>a</sup>	Rat-a	Rat-u	Rat-a

The plasmid pBS 3.3/1 (Rada et al., PNAS USA, 87:2167-2171, 1990) containing the wild type RT1.A<sup>a</sup> cDNA was used as a template for PCR amplification reactions between the 5' and 3' flanking outside primers (A and L), each containing an EcoR I site, and two internal overlapping SOEing primers containing the base substitutions. The N<sup>HLA-A2.1</sup> - RT1.A<sup>a</sup> mutant bears N-terminal nucleotides encoding the first 20 amino acids of human HLA-A2.1 in the first beta-strand and loop of the alpha-1 domain. Three PCR reactions were used to change nucleotides encoding Leu<sup>5</sup> to Met, Tyr<sup>9</sup> to Phe, Ala<sup>11</sup> to Ser and Leu<sup>17</sup> to Arg, using the internal primers B and C. Figure 5A shows the products of the first PCR reaction (primers A and B; 140 base pair, lane 2) and the second PCR reaction (primers C and L; 1490 base pairs, lane 3), which were SOEd in the third PCR reaction (primers A and L) to produce the 1.6 kb chimeric cDNA (lane 4).

The alpha-1h<sup>u</sup> RT1.A<sup>a</sup> cDNA contained RT1.A<sup>a</sup> sequences in the alpha-1 helix (amino acids 51-90), thereby changing Glu<sup>58</sup> to Asp, Gln<sup>62</sup> to Arg, Gln<sup>63</sup> to Glu, Arg<sup>65</sup> to Gln, Ile<sup>66</sup> to Lys, Glu<sup>69</sup> to Gly, Trp<sup>70</sup> to Asn, Ile<sup>73</sup> to Asn, Asp<sup>77</sup> to Ser, and Thr<sup>80</sup> to Asn by using the internal primers D and E. Figure 5B shows the first PCR reaction (primers A and D) generated a 300 base pair fragment (lane 2) that was SOEd into the

1310 base pair fragment generated by the second PCR (primers E and L, lane 3) in a third PCR reaction (lane 4).

The alpha-2D<sup>u</sup>-RT.1A<sup>a</sup> mutant contains the entire  
5 alpha-2<sup>u</sup> domain (amino acids 91-182), thus changing  
Glu<sup>97</sup> to Arg, Ser<sup>105</sup> to Thr, Glu<sup>148</sup> to Asp, Arg<sup>151</sup> to Gly,  
Try<sup>152</sup> to Val, Ser<sup>169</sup> to Arg, Leu<sup>174</sup> to His, and Ser<sup>182</sup> to  
Leu. Six internal primers: F, G, H, I, J, and K were  
utilized in four initial PCR reactions as shown in  
10 Figure 5C; PCR 1 (primers A and F, lane 2), PCR 2  
(primers G and H, lane 3); PCR 3 (primers I and J, lane  
4); and PCR 4 (primers K and L, lane 5). The four PCR  
fragments (400, 150, 120 and 990 base pairs) were SOEd  
in one final PCR reaction (primers A and L, lane 6).

15 Subcloning and Sequencing of PCR Products

The wild-type and mutated RT1.A<sup>a</sup> PCR products were  
individually ligated into the pT7Blue T-Vector  
(Novagen, Madison, WI), containing a single 3' dT  
residue at each end and an ampicillin resistance gene  
20 using T4 DNA ligase (Promega, Madison, WI). Epicurean  
Coli XL-1Blue MRF' competent cells (Stratagene, La  
Jolla, CA) were transformed by the ligation mixture  
into ampicillin-resistant cells and plated on LB  
ampicillin plates. Surviving colonies were separately  
25 grown in 5 ml LB medium containing ampicillin  
(100 mg/ml), plasmid DNA was extracted by mini-prep and  
digested by EcoR I to screen for the presence of the  
1.6 kb RT1.A<sup>a</sup> fragment. Positive colonies were  
separately cultured in 250 ml of LB ampicillin medium  
30 and plasmid DNA was extracted by maxi-pre using  
Qiagen-tips 500 (Qiagen, Chatsworth, CA) according to  
the manufacturer's specifications. Sequencing of  
plasmid DNA was performed in both directions with the  
fluorescence-based Taq dyedexy<sup>TM</sup> terminator cycle  
35 sequencing kit (Applied Biosystems, Foster City, CA)

using two outside and multiple internal primers. In brief, a 20  $\mu$ l reaction (TACS buffer, dNTP mix, dyedeoxy A, G, T and C terminators, ampliTag DNA polymerase, DNA templates and primers) was subjected to  
5 25 thermal cycling reactions (96°C at 30 sec.; 50°C at 15 sec.; and 60°C at 4 min.), purified on Centri-Sep spin columns (Princeton Separations, Adelphia, NJ) and loaded on an Applied Biosystems 373A DNA Sequencer. Data analysis was performed by a Macintosh II Ci  
10 computer using ABI 373A analysis software (version 1.1.1). The altered amino acid and nucleic acid sequences are shown in Figure 6, where changed residues are underlined and dots indicate no change from the wild-type RT1.A<sup>a</sup> sequences.

15 Transfection of BUF (RT1<sup>b</sup>) hepatoma cells

Wild-type or mutated RT1.A<sup>a</sup> cDNA subcloned in the eucaryotic expression vector pSG5 (stratagene, LaJolla, CA) containing the SV40 promoter were utilized for transfection of the BUF Morris hepatoma 7316A cells  
20 (Masuji et al.; 1974, Acta Med Okayama 28: 281-293) using the lipofectin reagent (Gibco, Grand Island, NY; Felinger et al., 1987). Lipofectin (25  $\mu$ l)-plasmid DNA (10  $\mu$ g; pSG5-RT1.A<sup>a</sup>:pSV2NEO; 10:1) complexes were added to 2 x 10<sup>5</sup> cells in a 4 ml serum-free medium (Complete  
25 RPMI; Sigma, St. Louis, MI) in 60 mm tissue culture dishes. Following a 6 hour incubation at 37°C, the medium was replaced with 10% Fetal Calf Serum (FCS)-RPMI. After 48 hours of further incubation, stable transfectants were selected by addition of 400  
30  $\mu$ g/ml (final concentration) of Geneticin (G418; Gibco, Grand Island, NY). Surviving colonies were expanded and analyzed for surface expression of TR1.A<sup>a</sup>.

Flow cytometry analysis was performed as described for Example 1, to detect surface expression of wild-



type or chimeric RT1.A<sup>a</sup> surface expression on transfected BUF(RT1<sup>b</sup>) cells.

5 All of the stable chimeric transfectants displayed similar levels of surface staining, i.e., greater than 90%, in contrast to their non-transfected hepatoma counterparts, which showed only approximately 38% surface staining. These results are shown in Figures 7A-E, and in Table 3.

TABLE 3

10

TRANSFECTANTS	SURFACE STAINING
Non-Transfected UF	38%
WT-RT1.A <sup>a</sup>	91.7%
$\alpha$ -1 <sup>b</sup> -RT1.A <sup>a</sup>	95.5%
15 $\alpha$ -2d <sup>u</sup> -RT1.A <sup>a</sup>	90.0%
N <sup>HLA-A2.1</sup> -RT1.A <sup>a</sup>	93.0%

EXAMPLE 320 IMMUNOGENICITY OF CHIMERIC RT1.A<sup>a</sup> ANTIGENS IN BUF HOSTS

Adult, male inbred buffalo rats (BUF; RT1<sup>b</sup>) were purchased from Harlan Sprague Darole (Indianapolis, IN) and housed in wire-bottomed cages with light/dark cycles. Rats were given free access to water and rat  
25 chow. The BUF hosts, which bear the same haplotype as the transfected hepatoma cell line, were injected subcutaneously with  $2 \times 10^7$  cells bearing either wild type<sup>a</sup> or the mutated chimeric antigens of Example 2, seven days prior to transplantation with an ACI (RT1<sup>a</sup>)  
30 or a Wistar Furth (WFu; RT<sup>u</sup>) heart allograft.

Cardiac transplantation was carried out as described for Example 1.

As shown in Table 4, injection of cells bearing chimeric MHC Class I antigen having a substituted  
35  $\alpha$ -2<sup>u</sup> domain sequence or a substituted N-terminal

HLA sequence, both immunized BUF (RT1<sup>b</sup>) hosts toward grafts from ACI (RT1<sup>a</sup>), but not WFu (RT1<sup>u</sup>) donors. In contrast, the chimeric antigen bearing substituted alpha-1<sup>u</sup> helical sequences sensitized BUF (RT1<sup>b</sup>) recipients to WFu (RT1<sup>u</sup>) but not to ACI (RT1<sup>a</sup>) donor alloantigens. These findings indicate that the alpha-1 helical region, but not the alpha-2 domain of RT1.A<sup>a</sup> and RT1.A<sup>u</sup> Class 1 alloantigens contains the dominant immunogenic epitopes that induce accelerated graft rejection. Further, the N-terminal<sup>a</sup> epitope present in the mutant substituted with alpha-1<sup>u</sup> helical sequences failed to induce accelerated rejection of ACI (RT1<sup>a</sup>) grafts.

TABLE 4

Donor-Recipient Strains	Immunogen	Polymorphic epitopes			Mean Survival Days $\pm$ SD	P
		$\alpha$ -1N	$\alpha$ -1h	$\alpha$ -2		
ACI (RT1 <sup>a</sup> )	—	-	-	-	5.4 $\pm$ 0.5	-
	WT-RT1.A <sup>a</sup>	a	a	a	3.3 $\pm$ 0.5	< 0.001
	N <sup>HLA-A2.1</sup> -RT1.A <sup>a</sup>	HLA	a	a	3.6 $\pm$ 0.5	< 0.001
	$\alpha$ 2 <sup>u</sup> -RT1.A <sup>a</sup>	a	a	u	3.8 $\pm$ 0.4	< 0.001
BUF (RT1 <sup>b</sup> )	$\alpha$ 1 <sup>u</sup> -RT1.A <sup>a</sup>	a	u	a	5.5 $\pm$ 0.5	NS
	—	-	-	-	6.0 $\pm$ 0	-
	WT-RT1.A <sup>a</sup>	a	a	a	5.6 $\pm$ 0.5	NS
	N <sup>HLA-A2.1</sup> -RT1.A <sup>a</sup>	HLA	a	a	5.5 $\pm$ 0.6	NS
WF(Rt1 <sup>u</sup> )	$\alpha$ 2 <sup>u</sup> -RT1.A <sup>a</sup>	a	a	u	5.4 $\pm$ 0.5	NS
	$\alpha$ 1 <sup>u</sup> -RT1.A <sup>a</sup>	a	u	a	4.4 $\pm$ 0.5	< 0.001
	—	-	-	-	6.0 $\pm$ 0	-
	WT-RT1.A <sup>a</sup>	a	a	a	5.6 $\pm$ 0.5	NS
BUF (RT1 <sup>b</sup> )	N <sup>HLA-A2.1</sup> -RT1.A <sup>a</sup>	HLA	a	a	5.5 $\pm$ 0.6	NS
	$\alpha$ 2 <sup>u</sup> -RT1.A <sup>a</sup>	a	a	u	5.4 $\pm$ 0.5	NS
	$\alpha$ 1 <sup>u</sup> -RT1.A <sup>a</sup>	a	u	a	4.4 $\pm$ 0.5	< 0.001
	—	-	-	-	6.0 $\pm$ 0	-

## EXAMPLE 4

IMMUNOGENICITY OF CHIMERIC RT1.A<sup>a</sup>  
ANTIGENS IN WF RECIPIENTS

Adult male inbred WF (RT1<sup>u</sup>) rats were purchased and housed as described for Example 3. WF rats bear a similar haplotype to the substituted sequences of the chimeric MHC Class 1 molecules  $\alpha$ -1h<sup>u</sup>-RT1.A<sup>a</sup> and  $\alpha$ -2d<sup>u</sup>-RT1.A<sup>a</sup>. These animals were immunized by subcutaneous injection with graded doses of  $1 \times 10^5$  -  $2 \times 10^7$  ACI (RT1<sup>a</sup>) spleen cells, or with hepatoma cells transfected

25

with the chimeric mutants WT-RT1.A<sup>a</sup>, N<sup>HLA-A2.1</sup>-RT1.A<sup>a</sup>,  $\alpha$ -1h<sup>u</sup>-RT1.A<sup>a</sup> or  $\alpha$ -2d<sup>u</sup>-RT1.A<sup>a</sup> seven days prior to transplantation with ACI (RT1<sup>a</sup>) heart allografts according to the methods described for Examples 1 and 3.

Immunization with 10x10<sup>6</sup> ACI (RT1<sup>a</sup>) spleen cells shortened the mean survival time of transplanted animals from 5.4±0.5 days to 2.3±0.5 days (p<0.001), while 20x10<sup>6</sup> WT-RT1.A<sup>a</sup> or N<sup>HLA-A2.1</sup>-RT1.A<sup>a</sup> (lacking N<sup>a</sup> epitope) accelerated ACI (RT1<sup>a</sup>) graft rejection to 2.8±0.4 days (p<0.001) and 4.2±0.4 days (p<0.001), respectively. These data are shown in Table 5.

TABLE 5

Donor-Recipient Strain	Immunogen	Polymorphic epitopes $\alpha$ -1-N $\alpha$ -1-h $\alpha$ -2			Mean Survival Days $\pm$ SD	P
ACI (RT1 <sup>a</sup> )	---	-	-	-	5.4±0.5	-
-	ACI Spleen Cells	a	a	a	2.3±0.5	<0.001
-	WT-RT1.A <sup>a</sup>	a	a	a	2.8±0.4	<0.001
WF (RT1 <sup>u</sup> )	N <sup>HLA-A2.1</sup> -RT1.A <sup>a</sup>	HLA	a	a	4.2±0.4	<0.001
	$\alpha$ 2 <sup>u</sup> -RT1.A <sup>a</sup>	a	a	u	4.9±0.4	NS
	$\alpha$ 1 <sup>u</sup> -RT1.A <sup>a</sup>	a	u	a	5.4±0.5	NS

As shown in Figure 8, in order to half the mean survival time (50% index), WF recipients must be injected with 7.5x10<sup>6</sup> ACI cells, 20x10<sup>6</sup> WT-RT1.A<sup>a</sup> or 57x10<sup>6</sup> N<sup>HLA-A2.1</sup>-RT1.A<sup>a</sup> transfectants.

However, administration of 20x10<sup>6</sup>  $\alpha$ -1h<sup>u</sup>-RT1.A<sup>a</sup> transfectants, which lack the  $\alpha$ -1<sup>a</sup> helical epitope, failed to induce accelerated rejection of ACI (RT1<sup>a</sup>) grafts (mean survival time: 5.4±0.5, NS; Fig. 8).

This data confirms the presence of an immunodominant

SUBSTITUTE SHEET (RULE 26)

immunogenic epitope in this region. The immunogenic difference between WT-RT1.A<sup>a</sup> and N<sup>HLA-A2.1</sup>-RT1.A<sup>a</sup> transfectants ( $p < 0.001$ ; Fig. 8) suggests that substitution of the N-terminus eliminates a subdominant immunogenic epitope.

In contrast, the putatively immunogenic N<sup>a</sup> and  $\alpha$ -1h<sup>a</sup> epitopes present in the  $\alpha$ -2d<sup>u</sup>-RT.1A<sup>a</sup> chimeric transfectant failed to immunize WF recipients (mean survival time:  $4.9 \pm 0.4$ , NS; Fig. 8), although this mutant sensitized BUF (RT1<sup>u</sup>) animals against ACI (RT1<sup>a</sup>) hearts (see Example 3, Table 4). Host-type  $\alpha$ -2d<sup>u</sup> flanking sequences downregulated host responses toward immunogenic donor-type  $\alpha$ -1<sup>a</sup> epitopes.

To confirm this downregulation, limiting dilution analysis was performed to quantitate the *in vitro* frequency of anti-ACI cytotoxic T cells (fTc) among the lymph node (LN) cells in normal and immune WF rats.

#### Limiting dilution analysis

A set of 24 replicates of each serial dilution of responder cells from 1:25,600 to 1:400 were seeded into 96-well round bottomed microtiter plates containing  $5 \times 10^4$  irradiated (2000 rads) allogeneic splenic stimulators per well in complete RPMI 1640 medium supplemented with 10% heat inactivated FCS and 10 units/ml of purified IL-2 (Collaborative Research Inc., Bedford, MA), using the methods described in Ito et al., 1990, Transplantation 49: 422-428. After 7 days of incubation at 37°C., the cytotoxic activity of each well was assessed during an additional 6 hour incubation at 37°C. with  $1 \times 10^4$  ACI or WF target cells previously stimulated with Concanavalin A (Con A) (3-day) and labeled with specific activity 200-500 mCi/mg Cr; Amersham, Arlington, IL). Release of <sup>51</sup>Cr from supernates harvested using a cartridge collection

system (Skatron Inc., Sterling, VA) was measured in a gamma counter.

Positive results were defined as values exceeding the mean spontaneous chromium release by more than 3 standard deviations (SD). Minimum chi-square estimates with 95% confidence limit of the fTc were obtained by the Poisson distribution relationship between responder-cell number and the natural logarithm of the fraction of negative cells. A divergence less than 10% between the maximum likelihood estimate and the minimum chi-square value with a probability greater than 0.05 as estimated from a chi-square table was regarded as consistent with "a single hit" Poisson model.

The data are shown in Figure 9. As expected, the administration of ACI spleen cells or WT-RT1.A<sup>a</sup> transfectants, both of which induce accelerated graft rejection, increased the fTc from 1:12638 in naive animals to 1:2548 and 1:3474, respectively. In contrast,  $\alpha$ -2d<sup>u</sup>-RT.1A<sup>a</sup> transfectants, which did not accelerate allograft rejection initially increased fTc to 1:3861, and then exhibited a V-shaped profile characteristic of negative regulatory cells whose activity is evident at fTc values less than 1:64000 (Florence et al., 1989, Transplantation 47:156, 162).

#### 25      Alloantibody detection

Anti-ACI (RT1<sup>a</sup>) binding alloantibodies were detected in the sera obtained from treated WF rats one week following treatment by incubation at 4°C. for 30 minutes of serially diluted experimental sera (1:4, 1:16 or 1:64) with ACI lymph nodes ( $3 \times 10^3$ ). After washing, 50  $\mu$ l of FITC-conjugated rabbit anti-rat IgG (1:250) or rabbit anti-rat IgM (1:100) were added for a second incubation. Cells were washed and fixed. The intensity of staining was expressed as mean channel shift (MCS), namely the difference between the sample's

mean fluorescence and the mean fluorescence obtained by the second fluoresceinated antibody only. Binding to anti-IgG is shown in Figure 10A, and to anti-IgM in Figure 10B.

5 Cytotoxic anti-ACI alloantibodies in experimental sera was detected by a two-stage complement-dependent antibody-mediated cytotoxicity assay. Sera were heat-inactivated at 56°C. for 30 minutes and serially diluted in a 96-well microtiter plate using HBSS with  
10 5% FCS.  $^{51}\text{Cr}$ -labeled ACI lymph node target cells ( $1 \times 10^5$ ) were added to each well and incubated at 4°C. for 30 minutes. Cells were washed prior to the addition of 50  $\mu\text{l}$  (1:8 dilution) of "low toxicity" rabbit complement (Cedar Lane, Toronto, Canada),  
15 followed by a 30-minute incubation at 37°C. Supernates were collected and radioactivity determined in a Beckman gamma counter. Maximum lysis was based on  $^{51}\text{Cr}$  release from labeled targets upon treatment with 0.8% Triton (Sigma, St. Louis, MO). The background count  
20 obtained by incubation with complement alone was less than 10% maximum lysis. The percent specific lysis was determined as:

$$\% \text{ specific lysis} = \frac{(\text{experimental} - \text{complement background})}{\text{maximum} - \text{complement background}} \times 100$$

25

The presence of cytotoxic antibody is shown in Figure 10C.

The injection of  $\alpha$ -2d<sup>u</sup>-RT1.A<sup>a</sup> transfectants into WF (RT1<sup>u</sup>) hosts failed to stimulate the production  
30 anti-RT1<sup>a</sup> alloantibodies. In contrast, transfectants bearing WT-RT1.A<sup>a</sup>, N<sup>HLAA-A2.1</sup>-RT1.A<sup>a</sup>, and  $\alpha$ -1h<sup>u</sup>-RT1.A<sup>a</sup> all evoked the production of non-complement-dependent IgG, but not IgM, antibodies. These results demonstrated that the combination of donor-type  $\alpha$ -1<sup>a</sup> immunogenic  
35 domain with recipient-type  $\alpha$ -2<sup>u</sup> domain induces a potent

regulatory response that inhibits sensitization toward allografts.

# EXAMPLE 5

## IMMUNOGENICITY OF CHIMERIC RT1.A<sup>a</sup> ANTIGENS IN ACI RECIPIENTS

WF (RT1<sup>u</sup>) spleen cells, wild type, or chimeric-RT1.A<sup>a</sup> transfectants ( $2 \times 10^7$ ) were injected subcutaneously into ACI (RT1<sup>a</sup>) recipients, which bear a similar haplotype to the backbone of the chimeric antigens of Example 2, seven days prior to grafting WF (RT1<sup>u</sup>) hearts, using the methods and analysis described in the preceding examples. The mean survival times of the treated animals are shown in Table 6 and Figure 11.

TABLE 6

IMMUNOGEN	MEAN SURVIVAL TIME DAYS $\pm$ SD	P
----	$5.4 \pm 0.6$	--
WF spleen cells	$4.0 \pm 0.7$	$< 0.01$
WT-RT1.A <sup>a</sup>	$5.5 \pm 0.5$	NS
N <sup>HLA-A2.1</sup> -RT1.A <sup>a</sup>	$8.7 \pm 1.0$	$< 0.001$
$\alpha$ -2d <sup>u</sup> -RT1.A <sup>a</sup>	$9.2 \pm 1.3$	$< 0.001$
$\alpha$ 1h <sup>u</sup> -RT1.A <sup>a</sup>	$14.0 \pm 10.3$	$< 0.001$

WF spleen cells shortened the mean survival time of transplant recipients from  $5.4 \pm 0.6$  days to  $4.0 \pm 0.7$  days ( $p < 0.01$ ), while the syngeneic WT-RT1.A<sup>a</sup> transfectants were not effective ( $5.5 \pm 0.5$ ; NS). N<sup>HLA-A2.1</sup>-RT1.A<sup>a</sup>,  $\alpha$ -2d<sup>u</sup>-RT1.A<sup>a</sup> and  $\alpha$ -1h<sup>u</sup>-RT1.A<sup>a</sup> transfectants all modestly prolonged the mean survival time of transplanted WF (RT1<sup>u</sup>) hearts from  $5.9 \pm 0.6$  days in untreated controls to  $8.7 \pm 1.0$  days ( $p < 0.01$ ),  $9.2 \pm 1.3$

days ( $p < 0.001$ ) and  $14.0 \pm 10.3$  days, respectively ( $p < 0.01$ ).

Furthermore, as shown in Table 7 and Figure 12, immunization with transfectants bearing  $N^{HLA-A2.1}$ -RT1.A<sup>a</sup>,  $\alpha$ -2d<sup>u</sup>-RT1.A<sup>a</sup> or  $\alpha$ -1h<sup>u</sup>-RT1.A<sup>a</sup> reduced the fTc toward WF alloantigens among lymph node cells of ACI (RT1<sup>a</sup>) rats, from 1:11264 in naive animals to 1:15572, 1:20689 and 1:65622, respectively. In contrast, immunization with WF spleen cells increased the fTc to 1:7541. These findings demonstrate the potential tolerogenicity of chimeric RT1.A<sup>a</sup> molecules, particularly those bearing donor  $\alpha$ -1 helix flanked by recipient N-terminal and  $\alpha$ -2 domain sequences, even upon immunogenic subcutaneous delivery.

TABLE 7

IMMUNOGEN	FREQUENCY OF ANTI-WF Tc CELLS
Naive control	1:11265
WF spleen cells	1:7541
WT-RT1.A <sup>a</sup>	1:13653
$N^{HLA-A2.1}$ -RT1.A <sup>a</sup>	1:15572
$\alpha$ -2d <sup>u</sup> -RT1.A <sup>a</sup>	1:20689
$\alpha$ -1h <sup>u</sup> -RT1.A <sup>a</sup>	1:65622

EXAMPLE 6INDUCTION OF TOLERANCE BY  $\alpha$ -1<sup>u</sup>-RT1.A<sup>a</sup> TO RT1<sup>u</sup> ALLOGRAFTS IN RT1<sup>a</sup> RECIPIENTS

The tolerogenicity of quasi-self chimeric antigens was further examined in the clinically relevant model of peri-transplant administration of antigen in combination with CsA therapy. This model is described, for example in Didlake et al, 1988 Transplantation 46:743-747; Florence et al., 1989 Transplantation



47:156-162; Ito et al., 1990 Transplantation 49:422-428; Hamashima et al., 1994, in press; Yasumura et al., 1983 Transplantation 36:603-609.

In addition to a seven day oral CsA course  
5 (10mg/kg; day 0-6), ACI (RT1<sup>a</sup>) recipients of WF (RT1<sup>u</sup>) hearts received a single immediately pre-operative, portal venous injection of 3M KCl extract (10mg) prepared from N<sup>HLA-A2.1</sup>-RT1.A<sup>a</sup>,  $\alpha$ -1h<sup>u</sup>-RT1.A<sup>a</sup> or  $\alpha$ -2d<sup>u</sup>-RT1.A<sup>a</sup> transfectants, from non-transfected BUF hepatoma  
10 cells (RT1<sup>b</sup>), or from donor-type WF (RT1<sup>u</sup>) hepatocytes.

The KCl-extracts were prepared from cells by treatment for 18 hours with 3m KCl followed by configuration, concentration of protein and dialysis  
15 with PBS as described in Reisfeld and Kahan, 1970, Fed. Proc. 29:2034-2040.

MHC antigen (e-HAg) was extracted with 3M KCl from normal BUF hepatoma cells, WT or from stable chimeric transfectants, as previously described (Reisfeld and  
20 Kahan, 1970, Fed. Proc. 29:2034-2040). The MHC antigen, e-HAg (10 mg) was administered via the portal vein on the day of transplantation immediately followed by 7 daily doses of 10 mg/kg/day of CsA delivered by oral gavage from day 0 to 6. CsA powder was obtained  
25 from Sandoz (Basel, Switzerland) and dissolved in a mixture of 1% ethyl alcohol and 99% Cremophor (Sigma, St. Louis, MO). The data are shown in Table 8 and Figure 13.

TABLE 8

	e-HAg Antigen	CsA	Mean $\pm$ SD Survival (Days)	P
	-	-	5.4 $\pm$ 0.6	-
	-	+	16.2 $\pm$ 1.6	-
5	Wfu liver (RT1 <sup>u</sup> )	+	20.4 $\pm$ 1.1	
	BUF Hepatoma (RT1 <sup>b</sup> )	+	16.5 $\pm$ 1.2	
	WT-RT1.A <sup>a</sup>	+	21.6 $\pm$ 1.2	
	N <sup>HLA-A2.1</sup> -RT1.A <sup>a</sup>	+	17.8 $\pm$ 0.8	
10	$\alpha$ -2d <sup>u</sup> - RT1.A <sup>a</sup>	+	19.2 $\pm$ 2.2	
	$\alpha$ -1h <sup>u</sup> - RT1.A <sup>a</sup>	+	170	< 0.001

Administration of CsA alone prolonged WF heart allograft survival to 16.2 $\pm$ 1.6 days. There was no additional effect of KCl extracts from WF (RT1<sup>u</sup>) hepatocytes, WT-RT1.A<sup>a</sup>, N<sup>HLA-A2.1</sup>-RT1.A<sup>a</sup>,  $\alpha$ -2d<sup>u</sup>-RT1.A<sup>a</sup> transfectants or non-transfected BUF hepatoma cells (Fig. 10). In contrast,  $\alpha$ -1h<sup>u</sup>-RT1.A<sup>a</sup> extracts induced indefinite survival in 80 percent of recipients (mean survival time >170 days, p<0.001).

Among the ACI (RT1<sup>a</sup>) recipients bearing WF (RT1<sup>u</sup>) heart allografts for more than 60 days, five accepted donor-type WF (RT1<sup>u</sup>) secondary heterotopic heart grafts (mean survival time >120 days), while three promptly rejected third-party Brown Norway (RT1<sup>n</sup>) secondary heterotopic heart transplants (mean survival time 7.0 $\pm$ 1.7). The secondary transplants were anastomosed to neck vessels.

Subsequently, these tolerant ACI recipients accepted donor-type WF skin allografts for more than 21 days (n=8) but rejected third-party Brown Norway skin allografts within 8.01 $\pm$ 0.0 days.

These results showed that flanking  $\alpha$ -1 immunogenic epitopes with syngeneic sequences in addition to CsA induces donor-specific transplantation tolerance.

Having described the invention above, various modifications of the techniques, procedures, material and equipment will be apparent to those in the art. It is intended that all such variations within the scope  
5 and spirit of the appended claims be embraced thereby.

WE CLAIM:

1           1.    A chimeric major histocompatibility complex  
2    Class I molecule comprising:  
3                an alpha-1 domain which alpha-1 domain  
4    includes an N-terminal region and a helical region; and  
5                an alpha-2 domain;  
6                wherein the helical region of the alpha-1  
7    domain has been substituted with a corresponding  
8    helical region of an alpha-1 domain of a different  
9    allelic major histocompatibility Class I molecule.

1           2.    The chimeric molecule of claim 1, wherein the  
2    substituted helical region is matched to a specified  
3    donor's allelic type major histocompatibility complex  
4    Class I molecule.

1           3.    The chimeric molecule of claim 1, wherein the  
2    N-terminal region and alpha-2 domain are matched to a  
3    specified recipient's allelic type major  
4    histocompatibility complex Class I molecule.

1           4.    A chimeric major histocompatibility complex  
2    Class I molecule comprising:  
3                an alpha-1 domain which includes a specified  
4    recipient's allelic type N-terminal region and a  
5    specified donor's allelic type helical region; and  
6                an alpha-2 domain of the specified  
7    recipient's allelic type,  
8                wherein the specified recipient and donor  
9    types are different allelic types of major  
10   histocompatibility Class I molecules.

1           5.    A chimeric gene encoding a major  
2   histocompatibility Class I molecule, the gene  
3   comprising:  
4                nucleic acid sequences encoding a specified  
5   recipient's allelic type N-terminal polymorphic alpha-1  
6   region; and  
7                nucleic acid sequences encoding a specified  
8   donor's allelic type polymorphic alpha-1 helical  
9   region; and  
10               nucleic acid sequences encoding an alpha-2  
11   domain of the specified recipient's allelic type,  
12                wherein the recipient and donor types are  
13   different allelic types of major histocompatibility  
14   complex Class I molecules.

1           6.    A pharmaceutical composition for inducing  
2   recipient tolerance to a donor graft, said composition  
3   comprising in a pharmaceutically acceptable carrier, an  
4   effective tolerance-inducing amount of:  
5                a chimeric major histocompatibility complex  
6   Class I molecule having an alpha-1 domain which  
7   includes a specified recipient-type N-terminal region  
8   and a specified donor-type helical region, and an  
9   alpha-2 domain of the specified recipient-type,  
10                wherein allelic major histocompatibility  
11   complex Class I type of the donor and the recipient  
12   differ, and  
13                wherein the N-terminal region of the alpha-1  
14   domain and the alpha-2 domain are of the same allelic  
15   type as the recipient, and the helical portion of the  
16   alpha-1 domain is of the same allelic type as the  
17   donor.

1           7.    The pharmaceutical composition of claim 6,  
2    wherein said chimeric molecule is provided as an  
3    extract of cells expressing the molecule.

1           8.    The pharmaceutical composition of claim 6,  
2    wherein said chimeric molecule is provided as whole  
3    cells expressing the molecule.

1           9.    The pharmaceutical composition of claim 6,  
2    wherein said chimeric molecule is provided as purified  
3    glycoprotein.

1           10.   A method for inducing recipient tolerance to  
2    a donor graft comprising the steps of:  
3                administering to a recipient an effective  
4    tolerance-inducing amount of a chimeric major  
5    histocompatibility complex Class I antigen wherein the  
6    N-terminal portion of the alpha-1 domain and the alpha-  
7    2 domain are of the recipient's allelic type, and the  
8    alpha-1 helical region is of the donor's allelic type  
9    and the recipient and donor allelic types differ.

1           11.   The method of claim 10, wherein said  
2    administering is at the time of donor graft  
3    transplantation.

1           12.   The method of claim 10 further comprising  
2    administration of cyclosporin.

1           13.   The method of claim 12 wherein said  
2    cyclosporin is administered daily for approximately  
3    seven days post-transplantation.

1           14. The method of claim 13 wherein said  
2   administration is of a single peri-operative dose of  
3   the chimeric molecule.

1           15. The method of claim 10, wherein said chimeric  
2   molecule is in the form of a cellular extract.

1           16. The method of claim 10, wherein said chimeric  
2   molecule is in the form of cells expressing the  
3   molecule.



1           17. The method of claim 10, wherein said chimeric  
2   molecule is in the form of substantially purified  
3   glycoprotein.

1           18. The method of claim 10, wherein said  
2   administration is by injection.

1           19. The method of claim 18, wherein said  
2   injection is into the portal vein.

1           20. The method of claim 10, wherein said  
2   administration inhibits production of anti-donor  
3   antibodies in the recipient.


1 / 11

FIGURE 1FIGURE 2A - 2F

SUBSTITUTE SHEET (RULE 26)



2 / 1 1

FIGURE 3

SUBSTITUTE SHEET (RULE 26)




FIGURE 4

SUBSTITUTE SHEET (RULE 26)

4 / 11




FIG. 5A




FIG. 5B




FIG. 5C






5 / 1 1

WT-RT1A <sup>a</sup>	5	L	R	Y	F	Y	T	A	V	S	R	P	G	L	G	E	P	R	F	I	A	24
	94	ctg	cgg	tat	ttc	tac	acc	gcc	gtg	tcc	cgg	ccc	ggc	ctc	ggg	gag	ccc	cgg	ttc	atc	gct	153
NHLA-A2.1-RT1A <sup>a</sup>																						
WT-RT1A <sup>a</sup>	58	E	Y	W	E	Q	Q	T	R	I	A	K	E	W	E	Q	I	Y	R	V	D	77
	253	gag	tat	tgg	gag	cag	cag	aca	cgg	atc	gcc	aag	gaa	tgg	gag	cag	att	tac	cga	gtg	gac	312
[a <sub>1</sub> <sup>u</sup> ]-RT1A <sup>a</sup>																						
WT-RT1A <sup>a</sup>	78	L	R	T																		
	313	ctg	agg	acc																		
[a <sub>1</sub> <sup>u</sup> ]-RT1A <sup>a</sup>																						
WT-RT1A <sup>a</sup>	97	E	M	Y	G	C	D	V	G	S	D	G	S	L	L	R	G	Y	R	Q	D	116
	370	gag	atg	tat	ggc	tgt	gac	gtg	ggg	tcg	gac	ggg	agc	ctc	ctc	cgc	gga	tat	agg	cag	gac	429
[a <sub>2</sub> <sup>u</sup> ]-RT1A <sup>a</sup>																						
WT-RT1A <sup>a</sup>	143	T	R	N	K	W	E	R	A	R	Y	A	E	R	L	R	A	Y	L	E	G	162
	508	acc	cgg	aac	aag	tgg	gag	cgg	gct	cgt	tat	gca	gag	aga	ctc	agg	gcc	tac	ctg	gag	ggc	567
[a <sub>2</sub> <sup>u</sup> ]-RT1A <sup>a</sup>																						
WT-RT1A <sup>a</sup>	163	T	C	V	E	W	L	S	R	Y	L	E	L	G	K	E	T	L	L	R	S	182
	568	acc	tgt	gtg	gag	tgg	ctc	agc	aga	tac	ctg	gag	ctc	ggg	aag	gag	aca	ctg	ctg	cgc	tca	627
[a <sub>2</sub> <sup>u</sup> ]-RT1A <sup>a</sup>																						

FIGURE 6


SUBSTITUTE SHEET (RULE 26)

6 / 1 1

FIG. 7AFIG. 7BFIG. 7CFIG. 7DFIG. 7E


SUBSTITUTE SHEET (RULE 26)

7 / 1 1



FIGURE 8

SUBSTITUTE SHEET (RULE 26)

8 / 1 1



FIGURE 9

SUBSTITUTE SHEET (RULE 26)

FIGURE 10AFIGURE 10B



10 / 1 1

FIGURE 10CFIGURE 11

SUBSTITUTE SHEET (RULE 26)

11/11




FIGURE 12




FIGURE 13

SUBSTITUTE SHEET (RULE 26)

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/05946

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07K 1/00; C07H 21/04; A61K 38/00, 48/00; A01N 63/00  
US CL : 530/350+; 536/23.4; 514/12; 424/93.21

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/350+; 536/23.4; 514/12; 424/93.21

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Chemical Abstracts

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	The EMBO Journal, Volume 7, No. 11, issued 1988, W.A. Jefferies et al, "Cytolytic T-Cells Recognize a Chimeric MHC Class I Antigen Expressed in Influenza A Infected Transgenic Mice", pages 3423-3431, see especially page 3428, col. 2, parag. 3 to page 3429, end.	1-4 and 6-20
X	Journal of Experimental Medicine, Volume 173, issued April 1991, A. Vitiello et al, "Analysis of the HLA-Restricted Influenza-Specific Cytotoxic T Lymphocyte Response in Transgenic Mice Carrying a Chimeric Human-mouse Class I Major Histocompatibility Complex", pages 1007-1015, see especially page 1012, parag. 2 to page 1013 to parag. 3.	1-4 and 6-20

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

26 JULY 1995

Date of mailing of the international search report

15 AUG 1995

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DEBORAH CROUCH, PHD

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)\*

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/05946

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Journal of Experimental Medicine, Volume 194, issued January 1994, J.M. Vyas et al, "Availability of Endogenous Peptides Limits Expression of an M3a-Ld Major Histocompatibility Complex Class I Chimera", pages 155-165, see especially page 162, col. 2, parag. 4 to page 163.	1-4 and 6-20

Form PCT/ISA/210 (continuation of second sheet)(July 1992)\*

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/05946

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:  
1-4 and 6-20
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING**

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-4, drawn to a chimeric major histocompatibility complex Class I molecule.

Group II, claim(s) 5, drawn to a chimeric gene encoding a chimeric major histocompatibility complex Class I molecule.

Group III, claim(s) 6-15 and 17-20, drawn to a pharmaceutical composition comprising a chimeric major histocompatibility complex Class I molecule and a carrier, and a method for inducing tolerance.

Group IV, claim(s) 16, drawn to a method for inducing tolerance by administering cells expressing a chimeric major histocompatibility complex Class I molecule

The inventions listed as Groups I-IV do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The invention of group I, a first product, and the invention of group II, a second product, do not share a special technical feature as the protein of group I is composed of amino acid residues and the gene of group II is composed of nucleic acid residues. In addition the products of groups I and II are of separate uses; the protein can be used to produce antibodies and the gene can be used as a probe in a hybridization assay. The inventions of group I, a first product, and the invention of group III, a third product, do not share a special technical feature. The protein of group I can be used as an antigen in the formation of antibodies. The pharmaceutical composition of group III used in the induction of immune tolerance. The invention of group I, a first product, and the invention of group IV, a second method of using the first product, do not share a special technical feature. The invention of group IV requires that cells expressing the chimeric MHC Class I molecule be used in treatment. The protein of group I can be used in the production of antibodies. The invention of group II, to a second product, and the invention of group III, to a third product, do not share a special technical feature. The gene of group II is composed of nucleic acid residues and the protein of group III is composed of amino acid residues. The gene can be used for a probe in hybridization assays and the protein can be used in the production of antibodies. The invention of group II, to a second product, and the invention of group IV, to a second method of using, do not share a special technical feature. The gene can be used in hybridization assays. The invention of group III and group IV do not share a special technical feature. The method of treatment in group III requires the administration of protein and the method of treatment in group IV requires the administration of cells expressing the chimeric MHC Class I molecule. The methods of administration and the method of evaluation are materially separate. Thus, the claims are not solinked by a special technical feature with the meaning of PCT Rule 13.2 so as to form a single general inventive concept.